CL2014001073A1 - Anticuerpos humanizados que reconocen alfa-sinucleina ; metodo para detectar cuerpos de lewy; metodo para inhibir la agregacion de sinucleina o reducir los cuerpos de lewy. - Google Patents
Anticuerpos humanizados que reconocen alfa-sinucleina ; metodo para detectar cuerpos de lewy; metodo para inhibir la agregacion de sinucleina o reducir los cuerpos de lewy.Info
- Publication number
- CL2014001073A1 CL2014001073A1 CL2014001073A CL2014001073A CL2014001073A1 CL 2014001073 A1 CL2014001073 A1 CL 2014001073A1 CL 2014001073 A CL2014001073 A CL 2014001073A CL 2014001073 A CL2014001073 A CL 2014001073A CL 2014001073 A1 CL2014001073 A1 CL 2014001073A1
- Authority
- CL
- Chile
- Prior art keywords
- lewy bodies
- synuclein
- reduce
- humanized antibodies
- detect
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161553131P | 2011-10-28 | 2011-10-28 | |
| US201261711208P | 2012-10-08 | 2012-10-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2014001073A1 true CL2014001073A1 (es) | 2014-12-19 |
Family
ID=48168610
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2014001073A CL2014001073A1 (es) | 2011-10-28 | 2014-04-25 | Anticuerpos humanizados que reconocen alfa-sinucleina ; metodo para detectar cuerpos de lewy; metodo para inhibir la agregacion de sinucleina o reducir los cuerpos de lewy. |
Country Status (33)
| Country | Link |
|---|---|
| US (7) | US8609820B2 (es) |
| EP (2) | EP2771031B1 (es) |
| JP (4) | JP5775974B2 (es) |
| KR (1) | KR101600733B1 (es) |
| CN (2) | CN104334184B (es) |
| AU (3) | AU2012328530A1 (es) |
| BR (1) | BR112014010198B1 (es) |
| CA (1) | CA2853531C (es) |
| CL (1) | CL2014001073A1 (es) |
| CO (1) | CO7020875A2 (es) |
| CY (1) | CY1120398T1 (es) |
| DK (2) | DK3378535T5 (es) |
| ES (2) | ES2669395T3 (es) |
| FI (1) | FI3378535T3 (es) |
| HK (1) | HK1252895A1 (es) |
| HR (2) | HRP20230065T1 (es) |
| HU (2) | HUE061978T2 (es) |
| IL (2) | IL232264B (es) |
| LT (2) | LT2771031T (es) |
| MX (2) | MX370234B (es) |
| MY (1) | MY165038A (es) |
| PE (1) | PE20141568A1 (es) |
| PH (1) | PH12014500938B1 (es) |
| PL (2) | PL3378535T3 (es) |
| PT (2) | PT2771031T (es) |
| RS (2) | RS63930B1 (es) |
| RU (1) | RU2743738C2 (es) |
| SG (1) | SG11201401857WA (es) |
| SI (2) | SI2771031T1 (es) |
| SM (2) | SMT202300048T1 (es) |
| UA (1) | UA116194C2 (es) |
| WO (1) | WO2013063516A1 (es) |
| ZA (1) | ZA201403864B (es) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9034337B2 (en) * | 2003-10-31 | 2015-05-19 | Prothena Biosciences Limited | Treatment and delay of outset of synucleinopathic and amyloidogenic disease |
| WO2005047860A2 (en) | 2003-11-08 | 2005-05-26 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
| HRP20230065T1 (hr) | 2011-10-28 | 2023-03-03 | Prothena Biosciences Limited | Humanizirana protutijela koja prepoznaju alfa-sinuklein |
| SG11201404321YA (en) | 2012-01-27 | 2014-08-28 | Neotope Biosciences Ltd | Humanized antibodies that recognize alpha-synuclein |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| US9856319B2 (en) * | 2012-12-28 | 2018-01-02 | Abbvie Inc. | Monovalent binding proteins |
| US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| AR097306A1 (es) | 2013-08-20 | 2016-03-02 | Merck Sharp & Dohme | Modulación de la inmunidad tumoral |
| JP2017501848A (ja) * | 2013-11-19 | 2017-01-19 | プロセナ バイオサイエンシーズ リミテッド | 便秘症状からのレビー小体病の免疫療法のモニター |
| US10562973B2 (en) | 2014-04-08 | 2020-02-18 | Prothena Bioscience Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
| US9732148B2 (en) | 2014-10-16 | 2017-08-15 | Genentech, Inc. | Anti-α-synuclein antibodies and methods of use |
| GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| CN109475616B (zh) | 2016-06-02 | 2022-10-18 | 麦迪穆有限责任公司 | 针对α-突触核蛋白的抗体及其用途 |
| US20180328943A1 (en) * | 2016-09-30 | 2018-11-15 | Enzo Biochem, Inc. | Immunomodulatory compositions and methods of use thereof |
| MA46836A (fr) | 2016-11-15 | 2019-09-25 | H Lundbeck As | Agents, utilisations et procédés pour le traitement d'une synucléinopathie |
| CA3042302A1 (en) | 2016-12-02 | 2018-06-07 | Prothena Biosciences Limited | Infrared assay detecting secondary structure profiles of alpha-synuclein |
| EP3555127B1 (en) | 2016-12-16 | 2024-12-18 | H. Lundbeck A/S | Agents, uses and methods |
| US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
| MX2019008029A (es) | 2017-01-06 | 2019-12-11 | Abl Bio Inc | Anticuerpo anti-alfa-sinucleina y su uso. |
| EP3567054A4 (en) | 2017-01-06 | 2021-03-10 | ABL Bio Inc. | ANTI-ALPHA SYN ANTIBODIES AND USES THEREOF |
| EA201991720A1 (ru) * | 2017-02-17 | 2020-01-20 | Бристол-Маерс Сквибб Компани | Антитела к альфа-синуклеину и их применения |
| WO2018204352A1 (en) | 2017-05-01 | 2018-11-08 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies against alpha-synuclein fibrils |
| EP3406632A1 (en) | 2017-05-23 | 2018-11-28 | S.I.S.S.A. Scuola Internazionale Superiore di Studi Avanzati | Ligands binding to prion protein for use in the treatment of synucleinopathies |
| EP3672635A4 (en) | 2017-08-23 | 2021-05-12 | The Trustees of The University of Pennsylvania | MONOCLONAL ANTIBODIES AGAINST PATHOLOGICAL ALPHA-SYNUCLEIN AND METHOD OF USING THEREOF |
| CN111886251A (zh) | 2017-12-14 | 2020-11-03 | Abl生物公司 | 抗a-syn/igf1r的双特异性抗体及其用途 |
| GB201720975D0 (en) * | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
| GB201720970D0 (en) | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
| NL2020520B1 (en) * | 2018-03-02 | 2019-09-12 | Labo Bio Medical Invest B V | Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders |
| EP3833435B1 (en) | 2018-08-09 | 2025-09-24 | F. Hoffmann-La Roche AG | Determination of parkinson's disease |
| TWI734279B (zh) | 2018-12-14 | 2021-07-21 | 美商美國禮來大藥廠 | 抗α-突觸核蛋白抗體及其用途 |
| KR102691493B1 (ko) * | 2019-06-14 | 2024-08-05 | 에이비엘바이오 주식회사 | α-SYN/IGF1R에 대한 이중 특이 항체 및 그 용도 |
| EP4400515A3 (en) | 2020-04-24 | 2024-10-23 | F. Hoffmann-La Roche AG | Enzyme and pathway modulation with sulfhydryl compounds and their derivatives |
| CN114516914B (zh) * | 2020-11-19 | 2023-04-28 | 东莞市朋志生物科技有限公司 | 抗n末端脑钠肽前体的抗体和检测n末端脑钠肽前体的试剂和试剂盒 |
| CN112710850A (zh) * | 2020-12-29 | 2021-04-27 | 苏州百志生物科技有限公司 | 一种检测人体液中α-突触核蛋白含量的试剂盒 |
| TWI824243B (zh) | 2021-05-05 | 2023-12-01 | 國立高雄大學 | 一種胜肽拓印導電聚合物及其用途 |
| CN113912712B (zh) * | 2021-12-15 | 2022-03-08 | 北京凯祥弘康生物科技有限公司 | 抗α-突触核蛋白的单克隆抗体的制备及其应用 |
| CN116102646A (zh) * | 2023-02-13 | 2023-05-12 | 贵安新区康顺生物科技有限公司 | 抗人-磷酸化突触核蛋白抗体及其应用 |
Family Cites Families (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| IE64738B1 (en) | 1990-03-20 | 1995-09-06 | Akzo Nv | Stabilized gonadotropin containing preparations |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| JP2000510813A (ja) | 1995-02-06 | 2000-08-22 | ジェネテイックス・インスティテュート・インコーポレイテッド | Ｉｌ−１２用処方 |
| DE19539493A1 (de) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Starker homologer Promotor aus Hamster |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| DE60045319D1 (de) | 1999-02-05 | 2011-01-13 | Samsung Electronics Co Ltd | Verfahren und Vorrichtung zum Wiederauffinden von Texturbildern |
| TWI255272B (en) * | 2000-12-06 | 2006-05-21 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
| MXPA05000511A (es) | 2001-07-12 | 2005-09-30 | Jefferson Foote | Anticuepros super humanizados. |
| GB0129260D0 (en) * | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
| EP1531864A4 (en) | 2002-05-13 | 2006-08-23 | Alexion Pharma Inc | HUMANIZED ANTIBODIES TO THE VENEZOLAN HORSEMEN ENZEPHALITIS VIRUS |
| US20080014194A1 (en) | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
| TW200509968A (en) * | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
| US9034337B2 (en) | 2003-10-31 | 2015-05-19 | Prothena Biosciences Limited | Treatment and delay of outset of synucleinopathic and amyloidogenic disease |
| US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| ES2293096T3 (es) | 2002-11-29 | 2008-03-16 | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | Nuevos genes de la fosfotransferasa de neomicina y procedimiento para la seleccion de celulas recombinantes de produccion elevada. |
| WO2004065419A1 (ja) * | 2003-01-22 | 2004-08-05 | Takeda Pharmaceutical Company Limited | 抗体およびその用途 |
| AU2004229335C1 (en) | 2003-04-04 | 2010-06-17 | Genentech, Inc. | High concentration antibody and protein formulations |
| US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
| DE10338531A1 (de) | 2003-08-19 | 2005-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Reklonierung von Produktionszellen |
| WO2005047860A2 (en) | 2003-11-08 | 2005-05-26 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
| JP2007512846A (ja) | 2003-12-04 | 2007-05-24 | ゼンコー・インコーポレイテッド | 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物 |
| US7022550B2 (en) | 2004-04-07 | 2006-04-04 | Gelcore Llc | Methods for forming aluminum-containing p-contacts for group III-nitride light emitting diodes |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| PL1820022T3 (pl) | 2004-11-10 | 2009-11-30 | Boehringer Ingelheim Pharma | Zastosowanie analizy metodą cytometrii przepływowej w optymalizacji strategii dla banków komórek jajnika chińskiego chomika |
| AR054428A1 (es) | 2005-03-08 | 2007-06-27 | Pharmacia & Upjohn Co Llc | Composiciones de anticuerpos anti factor estimulante de colonia de macrofagos (anti-m-csf) que tienen menores niveles de endotoxina |
| CA2657953A1 (en) * | 2005-07-19 | 2007-01-25 | University Of Rochester | Alpha-synuclein antibodies and methods related thereto |
| WO2007021255A1 (en) * | 2005-08-09 | 2007-02-22 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
| WO2007075283A2 (en) | 2005-12-06 | 2007-07-05 | Amgen Inc. | Polishing steps used in multi-step protein purification processes |
| NZ574188A (en) | 2006-07-14 | 2012-05-25 | Ac Immune Sa | Humanized antibody against amyloid beta |
| US20080124760A1 (en) | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
| US8147833B2 (en) | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| SG178804A1 (en) | 2007-02-23 | 2012-03-29 | Schering Corp | Engineered anti-il-23p19 antibodies |
| PL2118300T3 (pl) | 2007-02-23 | 2015-11-30 | Prothena Biosciences Ltd | Zapobieganie i leczenie synukleinopatii i amyloidozy |
| JP5467415B2 (ja) | 2007-03-02 | 2014-04-09 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | タンパク質製造の改良 |
| SI2132230T1 (sl) * | 2007-03-22 | 2014-07-31 | Genentech, Inc. | Apoptotska protitelesa, ki veĹľejo membransko-vezan IgE |
| MX2009010179A (es) | 2007-03-22 | 2010-03-15 | Imclone Llc | Formulaciones estables de anticuerpo. |
| EP2031064A1 (de) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Verfahren zur Steigerung von Proteintitern |
| ES2511844T3 (es) | 2007-12-21 | 2014-10-23 | F. Hoffmann-La Roche Ag | Formulación de anticuerpo |
| PT2237803E (pt) | 2007-12-28 | 2015-10-16 | Prothena Biosciences Ltd | Tratamento e profilaxia da amiloidose |
| DK2282758T3 (en) * | 2008-04-29 | 2019-02-25 | Bioarctic Ab | ANTIBODIES AND VACCINES FOR USE IN THERAPEUTIC AND DIAGNOSTIC PROCEDURES FOR ALPHA-SYNUCLEIN-RELATED DISORDERS |
| WO2009141239A1 (en) | 2008-05-20 | 2009-11-26 | F. Hoffmann-La Roche Ag | A pharmaceutical formulation comprising an antibody against ox40l, uses thereof |
| US20120276019A1 (en) | 2008-07-25 | 2012-11-01 | Diamedica Inc. | Tissue kallikrein for the treatment of parkinson's disease |
| WO2010069603A1 (en) * | 2008-12-19 | 2010-06-24 | Neurimmune Therapeutics Ag | Human anti-alpha-synuclein autoantibodies |
| NZ623910A (en) | 2009-07-28 | 2016-06-24 | Shire Human Genetic Therapies | Compositions and methods for treating gaucher disease |
| PL214940B1 (pl) | 2009-07-31 | 2013-09-30 | Lozano Platonoff Alberto | Mechanizm wskaznikowy automatycznego aplikatora, zwlaszcza do insuliny |
| AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
| EP2519537A4 (en) | 2009-12-29 | 2013-07-10 | Reddys Lab Ltd Dr | CLEANING PROTEINS |
| EP2366714A1 (en) * | 2010-03-03 | 2011-09-21 | Dr. Rentschler Holding GmbH & Co. KG | Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein |
| TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
| US9028830B2 (en) | 2010-04-08 | 2015-05-12 | JN Biosciences, LLC | Antibodies to CD122 |
| SG185428A1 (en) | 2010-06-08 | 2012-12-28 | Genentech Inc | Cysteine engineered antibodies and conjugates |
| WO2011155607A1 (ja) | 2010-06-11 | 2011-12-15 | 協和発酵キリン株式会社 | 抗ｔｉｍ－３抗体 |
| MX343376B (es) | 2010-07-15 | 2016-11-03 | Adheron Therapeutics Inc | Anticuerpos humanizados que tienen como objetivo el dominio ec1 de cadherina-11 y composiciones y metodos relacionados. |
| SG10201508401TA (en) | 2010-10-11 | 2015-11-27 | Abbvie Bahamas Ltd | Processes for purification of proteins |
| EP2673635A4 (en) | 2011-02-07 | 2015-08-12 | Neotope Biosciences Ltd | IMMUNOTHERAPY THROUGH APOE |
| US8619359B2 (en) | 2011-04-27 | 2013-12-31 | Howard Letovsky | Electronic microscope filter |
| WO2012160536A1 (en) | 2011-05-26 | 2012-11-29 | Dr Reddy's Laboratories Limited | Antibody purification |
| US9845327B2 (en) | 2011-06-22 | 2017-12-19 | The General Hospital Corporation | Treatment of proteinopathies |
| WO2013003680A1 (en) | 2011-06-30 | 2013-01-03 | Genentech, Inc. | Anti-c-met antibody formulations |
| CA2853112C (en) | 2011-10-25 | 2018-08-21 | Onclave Therapeutics Limited | Antibody formulations and methods |
| HRP20230065T1 (hr) | 2011-10-28 | 2023-03-03 | Prothena Biosciences Limited | Humanizirana protutijela koja prepoznaju alfa-sinuklein |
| AR088579A1 (es) | 2011-10-31 | 2014-06-18 | Genentech Inc | Formulaciones de anticuerpos |
| SG11201404321YA (en) | 2012-01-27 | 2014-08-28 | Neotope Biosciences Ltd | Humanized antibodies that recognize alpha-synuclein |
| RU2711552C2 (ru) | 2012-08-29 | 2020-01-17 | Ф. Хоффманн-Ля Рош Аг | Шаттл для гематоэнцефалического барьера |
| UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
| US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
| US10562973B2 (en) | 2014-04-08 | 2020-02-18 | Prothena Bioscience Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
| US10084674B2 (en) | 2015-09-09 | 2018-09-25 | International Business Machines Corporation | Virtual desktop operation and data continuity preservation |
-
2012
- 2012-10-26 HR HRP20230065TT patent/HRP20230065T1/hr unknown
- 2012-10-26 PT PT128444338T patent/PT2771031T/pt unknown
- 2012-10-26 HR HRP20180728TT patent/HRP20180728T1/hr unknown
- 2012-10-26 UA UAA201405767A patent/UA116194C2/uk unknown
- 2012-10-26 HU HUE18155441A patent/HUE061978T2/hu unknown
- 2012-10-26 AU AU2012328530A patent/AU2012328530A1/en not_active Abandoned
- 2012-10-26 US US13/662,261 patent/US8609820B2/en active Active
- 2012-10-26 RS RS20230054A patent/RS63930B1/sr unknown
- 2012-10-26 BR BR112014010198-1A patent/BR112014010198B1/pt active IP Right Grant
- 2012-10-26 EP EP12844433.8A patent/EP2771031B1/en active Active
- 2012-10-26 MY MYPI2014001215A patent/MY165038A/en unknown
- 2012-10-26 ES ES12844433.8T patent/ES2669395T3/es active Active
- 2012-10-26 CN CN201280053194.0A patent/CN104334184B/zh active Active
- 2012-10-26 CA CA2853531A patent/CA2853531C/en active Active
- 2012-10-26 LT LTEP12844433.8T patent/LT2771031T/lt unknown
- 2012-10-26 PL PL18155441.1T patent/PL3378535T3/pl unknown
- 2012-10-26 HU HUE12844433A patent/HUE037811T2/hu unknown
- 2012-10-26 RU RU2016101137A patent/RU2743738C2/ru active
- 2012-10-26 SI SI201231300T patent/SI2771031T1/en unknown
- 2012-10-26 JP JP2014539089A patent/JP5775974B2/ja active Active
- 2012-10-26 PE PE2014000613A patent/PE20141568A1/es not_active Application Discontinuation
- 2012-10-26 RS RS20180539A patent/RS57315B1/sr unknown
- 2012-10-26 PH PH1/2014/500938A patent/PH12014500938B1/en unknown
- 2012-10-26 SM SM20230048T patent/SMT202300048T1/it unknown
- 2012-10-26 PT PT181554411T patent/PT3378535T/pt unknown
- 2012-10-26 MX MX2014005038A patent/MX370234B/es active IP Right Grant
- 2012-10-26 EP EP18155441.1A patent/EP3378535B1/en active Active
- 2012-10-26 PL PL12844433T patent/PL2771031T3/pl unknown
- 2012-10-26 DK DK18155441.1T patent/DK3378535T5/da active
- 2012-10-26 DK DK12844433.8T patent/DK2771031T3/en active
- 2012-10-26 SI SI201232020T patent/SI3378535T1/sl unknown
- 2012-10-26 FI FIEP18155441.1T patent/FI3378535T3/fi active
- 2012-10-26 ES ES18155441T patent/ES2937409T3/es active Active
- 2012-10-26 KR KR1020147014374A patent/KR101600733B1/ko active Active
- 2012-10-26 SG SG11201401857WA patent/SG11201401857WA/en unknown
- 2012-10-26 LT LTEP18155441.1T patent/LT3378535T/lt unknown
- 2012-10-26 WO PCT/US2012/062290 patent/WO2013063516A1/en not_active Ceased
- 2012-10-26 CN CN201711166162.2A patent/CN107880123A/zh active Pending
- 2012-10-26 SM SM20180307T patent/SMT201800307T1/it unknown
-
2014
- 2014-01-15 US US14/156,441 patent/US9556259B2/en active Active
- 2014-04-25 CL CL2014001073A patent/CL2014001073A1/es unknown
- 2014-04-25 MX MX2019014658A patent/MX2019014658A/es unknown
- 2014-04-27 IL IL232264A patent/IL232264B/en active IP Right Grant
- 2014-05-26 CO CO14113186A patent/CO7020875A2/es unknown
- 2014-05-27 ZA ZA2014/03864A patent/ZA201403864B/en unknown
-
2015
- 2015-07-06 JP JP2015135643A patent/JP5960328B2/ja active Active
-
2016
- 2016-04-26 AU AU2016202622A patent/AU2016202622B2/en active Active
- 2016-06-22 JP JP2016123524A patent/JP6234511B2/ja active Active
- 2016-12-21 US US15/387,580 patent/US9884906B2/en active Active
-
2017
- 2017-10-24 JP JP2017205366A patent/JP6592059B2/ja active Active
- 2017-12-14 AU AU2017276296A patent/AU2017276296B2/en active Active
- 2017-12-28 US US15/857,104 patent/US10450369B2/en active Active
-
2018
- 2018-07-03 CY CY20181100693T patent/CY1120398T1/el unknown
- 2018-09-21 HK HK18112242.1A patent/HK1252895A1/zh unknown
-
2019
- 2019-05-20 US US16/417,309 patent/US10723792B2/en active Active
-
2020
- 2020-02-12 IL IL272615A patent/IL272615B/en unknown
- 2020-06-16 US US16/903,271 patent/US11345749B2/en active Active
-
2022
- 2022-04-26 US US17/730,074 patent/US12528858B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY2023014I1 (el) | Αντι il-36r αντισωματα | |
| CO7020875A2 (es) | Anticuerpos humanizados que reconocen la alfa-sinucleina | |
| DK3653645T3 (da) | Monoklonal interleukin-31-antistof | |
| DK3156416T3 (da) | Sekvenssymmetriske modificerede bispecifikke igg4-antistoffer | |
| CO6811812A2 (es) | Anticuerpo anti-b7-h3 | |
| HUE036663T2 (hu) | Készítmény anti-alfa4béta7 antitesthez | |
| HUE036664T2 (hu) | Készítmény anti-alfa4béta7 antitesthez | |
| BR112014013034A2 (pt) | método para produzir um anticorpo | |
| CR20140127A (es) | Anticuerpo anti-abtcr | |
| BR112013022797A2 (pt) | anticorpos anti-ctla4 humanizados | |
| HRP20160484T1 (hr) | Životinje koje izražavaju antitijela sa zajedničkim lakim lancem | |
| IL243311A0 (en) | Novel antibody frameworks | |
| DK2807188T3 (da) | Humaniserede antistoffer, der genkender alpha-synuclein | |
| PL3071595T3 (pl) | Humanizowane przeciwciało przeciw kalikreinie-2 | |
| BR112014011900A2 (pt) | um método de purificação de anticorpo | |
| BR112016003196A2 (pt) | método para separar anticorpos biespecíficos | |
| PL3088421T3 (pl) | Przeciwciała monoklonalne do zastosowania w diagnostyce i leczeniu nowotworów i choroby autoimmunologicznej | |
| EP2733382A4 (en) | TORQUE ROD | |
| IL241763B (en) | Maintenance of tagged search results | |
| BR112014008691A2 (pt) | anticorpos para cd1d | |
| BR112014025664A2 (pt) | Método para preparar composição de sal de alumínio | |
| LT2742068T (lt) | Nauji antikūnai prieš fosforilcholiną | |
| CO6841994A2 (es) | Anticuerpos | |
| FR2973145B1 (fr) | Atlas visuo-tactile. | |
| DOP2011000313A (es) | Anticuerpos especificos para caderin-17 |